Laboratorios Farmaceuticos Rovi, S.A./ADR
LABFFDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DMMET-01 | Phase 3 | Diabetes Type 2 | - | - |
Nimotuzumab | Phase 2 | Diffuse Intrinsic Brainstem Gliomas | - | - |
Frequently asked questions
What is in Laboratorios Farmaceuticos Rovi, S.A./ADR's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Laboratorios Farmaceuticos Rovi, S.A./ADR's (LABFF) pipeline across Phase 3, Phase 2. Its lead program is DMMET-01 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Laboratorios Farmaceuticos Rovi, S.A./ADR's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Laboratorios Farmaceuticos Rovi, S.A./ADR (LABFF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LABFF biotech catalysts?→
Add LABFF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Laboratorios Farmaceuticos Rovi, S.A./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.